Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by MediWound Ltd.

MediWound to Report Third Quarter 2024 Financial Results
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound to Report Second Quarter 2024 Financial Results
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces $25 Million Strategic Private Placement Financing
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound to Report First Quarter 2024 Financial Results
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound to Participate in Two Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
From MediWound Ltd.
Via GlobeNewswire
Tickers ENLV MDWD
MediWound to Report Third Quarter 2023 Financial Results
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD MMM
MediWound Deploys NexoBrid® for Emergency Supply
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
From MediWound Ltd.
Via GlobeNewswire
Tickers MDWD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.